Form 4: Corcept Exec Sells Shares, Exercises Options

Corcept Therapeutics President of Endocrinology, Sean Maduck, exercised stock options and sold a significant number of shares, alongside transferring shares to family trusts.

Summary

• Sean Maduck, President of Corcept Endocrinology, reported multiple transactions involving Corcept Therapeutics (CORT) common stock and stock options.
• On June 12, 2025, 10,024 shares of common stock were transferred without consideration from direct ownership to the Sean and Molly Maduck Living Trust.
• On July 3, 2025, an additional 40,000 shares of common stock were transferred without consideration from indirect ownership to the SNM 2025 Grantor Retained Annuity Trust.
• On August 1, 2025, Mr. Maduck exercised 35,007 stock options at an exercise price of $5.05 per share.
• Concurrently on August 1, 2025, Mr. Maduck sold a total of 35,007 shares of common stock in multiple transactions under a Rule 10b5-1 plan adopted on September 5, 2024.
• The sales occurred at weighted average prices of $67.5334 (27,865 shares, range $67.17-$68.10), $68.5247 (5,428 shares, range $68.17-$69.13), and $69.7008 (1,714 shares, range $69.48-$69.74).
• Following these transactions, Mr. Maduck directly holds 7,681 shares of common stock, which includes 1,877 shares underlying unvested restricted stock awards granted between September 3, 2024, and June 2, 2025.
• Indirect beneficial ownership includes 99,717 shares held by the Sean and Molly Maduck Living Trust, 40,000 shares held by the SNM 2025 Grantor Retained Annuity Trust, and 10,000 shares held by Duckhill Capital, LLC (beneficial ownership disclaimed except for pecuniary interest).
• Mr. Maduck also directly holds 21,986 unexercised stock options with an exercise price of $5.05, expiring on May 2, 2026.

Sentiment

Score: 4

Explanation: The exercise of options is positive, but the significant sale of shares by a key executive, even under a 10b5-1 plan, generally carries a negative sentiment as it reduces insider ownership.

Positives

• The exercise of 35,007 stock options at a low price of $5.05 indicates a significant unrealized gain on those options.
• The reporting person holds unvested restricted stock awards, indicating ongoing equity incentives tied to future performance.

Negatives

• A significant number of shares (35,007) were sold by a key executive, which can be perceived negatively by the market, even if pre-planned.

Future Outlook

NA

Management Comments

• Sean Maduck is identified as the President, Corcept Endocrinology.

Industry Context

NA

Related Party Transactions

• Transfer of 10,024 shares to the Sean and Molly Maduck Living Trust, of which the Reporting Person is a co-trustee.
• Transfer of 40,000 shares to the SNM 2025 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.

Stakeholder Impact

• Shareholders may view the insider selling as a negative signal, potentially impacting investor confidence.

Key Dates

Recommendation

While the executive exercised options at a low price, the subsequent sale of a substantial number of shares, even under a 10b5-1 plan, suggests a reduction in direct insider exposure. This could be interpreted as a neutral to slightly negative signal, warranting a 'hold' recommendation for investors to observe future developments rather than a strong buy or sell.

Keywords

Corcept Therapeutics, CORT, Sean Maduck, Insider Trading, Stock Options, Share Sale, SEC Form 4, 10b5-1 Plan, Trust Transfer, Biotechnology, Pharmaceuticals